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Objective
To review the current knowledge on the genetic alterations
involved in the development and progression of Barrett’s
esophagus-associated neoplastic lesions.
Summary Background Data
Barrett’s esophagus (BE) is a premalignant condition in which
the normal squamous epithelium of the esophagus is re-
placed by metaplastic columnar epithelium. BE predisposes
patients to the development of esophageal adenocarcinoma.
Endoscopic surveillance can detect esophageal adenocarci-
nomas when they are early and curable, but most of the ade-
nocarcinomas are detected at an advanced stage. Despite
advances in multimodal therapy, the prognosis for invasive
esophageal adenocarcinoma is poor. A better understanding
of the molecular evolution of the Barrett’s metaplasia to dys-
plasia to adenocarcinoma sequence may allow improved di-
agnosis, therapy, and prognosis.
Methods
The authors reviewed data from the published literature to
address what is known about the molecular changes thought
to be important in the pathogenesis of BE-associated neo-
plastic lesions.
Results
The progression of Barrett’s metaplasia to adenocarcinoma is
associated with several changes in gene structure, gene ex-
pression, and protein structure. Some of the molecular alter-
ations already showed promise as markers for early cancer
detection or prognostication. Among these, alterations in the
p53 and p16 genes and cell cycle abnormalities or aneuploidy
appear to be the most important and well-characterized mo-
lecular changes. However, the exact sequence of events is
not known, and probably multiple molecular pathways interact
and are involved in the progression of BE to adenocarcinoma.
Conclusions
Further research into the molecular biology of BE-associated
adenocarcinoma will enhance our understanding of the ge-
netic events critical for the initiation and progression of Bar-
rett’s adenocarcinoma, leading to more effective surveillance
and treatment.
Since 1970, the incidence of adenocarcinomas of the
esophagus has increased in many countries at a rate that
exceeds that of any other malignancy.1–5 It is now generally
accepted that esophageal adenocarcinomas develop from a
premalignant lesion of the esophagus, also referred to as
Barrett’s esophagus (BE). BE is a metaplastic change of the
normal squamous cell epithelium of the esophagus to a
columnar type as a result of longstanding gastroesophageal
reflux. Three subtypes of BE have been described, but the
specialized intestinal type is the only subtype clearly asso-
ciated with malignant transformation.6,7 The risk of esoph-
ageal adenocarcinoma in patients with BE appears to be
approximately 30- to 125-fold greater than that in the gen-
eral population, with an estimated incidence of 1 in 180
patient-years.8–11 Although high-grade dysplasia of BE is
generally considered a precursor to invasive carcinoma, the
assessment of novel biomarkers and better understanding of
the pathophysiology of Barrett’s adenocarcinoma may help
to identify patients at increased risk for malignant transfor-
mation. In addition, elucidating the genetic alterations lead-
ing to malignant transformation may someday lead to its
prevention.
It is generally accepted that a multistep process of genetic
and epigenetic alterations causes the transformation of a
normal cell into a malignant tumor cell. These alterations
render the cell independent of regulated proliferative and
cell death pathways and infuse the cells with proliferative,
invasive, and metastasizing capacities. As a consequence, a
malignant tumor is generated composed of cells with an
increased proliferative activity, a prolonged life span, and
metastasizing capacity. At least 5 to 10 genetic alterations
are necessary to generate the malignant phenotype, and
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most tumors are characterized by genomic instability, facil-
itating the accumulation of mutations. The genomic insta-
bility occurs in two different forms, one characterized by
microsatellite instability (MSI) and the other by chromo-
somal instability.12 The targets of the genomic instability
are four classes of genes:
1. Protooncogenes: These are dominant genes that all act
in signal transduction from extracellular stimuli to the nu-
cleus or in regulation of gene expression, and they have a
role in cell proliferation or inhibition of apoptosis. On
activation of protooncogenes by mutation, amplification,
translocation, and so forth, these genes turn into oncogenes
with unregulated, constitutive activity. This results in ex-
cessive stimulation of cell proliferation or prevention of
apoptosis, and both contribute to tumor formation.
2. Tumor suppressor genes: Tumor suppressor genes are
normal cellular genes that primarily are involved in cell
proliferation, apoptosis, cell adhesion, and gene expression
regulation. These are recessive genes, which implies that
both gene copies need to be inactivated to contribute to
tumorigenesis. Functional inactivation of tumor suppressor
genes can be caused by genetic as well as by epigenetic
phenomena: mutation, deletion of part of the gene, and
epigenetic silencing through promoter methylation.
3. Mismatch repair genes: Genetic instability can be
caused by impairment in DNA repair. This deficiency is
recognized in tumors by MSI or the replication error phe-
notype. The genes PMS1, PMS2, MLH1, MSH2, MSH6,
and the recently discovered MBD4 (MED1) are all associ-
ated with MSI.13,14 In tumors with underlying defects, con-
tractions or expansions of short repeat sequences (microsat-
ellites) can be found.15 The mismatch repair deficiency
leads to a genome-wide accumulation of mutations, also in
protooncogenes and tumor suppressor genes, and contrib-
utes as such to tumorigenesis.
4. Mitotic checkpoint genes. An inactivating mutation in
one copy of these genes has a dominant effect on the
phenotype (dominant-negative). Eight human genes with a
role in mitotic checkpoint control have been discovered.16
Inactivation of mitotic checkpoint genes results in chromo-
somal instability and an abnormal chromosome number
(aneuploidy).16 Mutation analysis of the human mitotic
checkpoint genes in aneuploid cancers revealed only a few
alterations. It is therefore anticipated that genes yet to be
discovered are responsible for most of the checkpoint de-
fects found in aneuploid cancers.
Genomic instability at the nucleotide or chromosomal
level ultimately leads to the activation of protooncogenes
and inactivation of tumor suppressor genes. There are no
protooncogenes or tumor suppressor genes that are activated
or deleted in all cancers. Even comparable cancers from the
same organ and cell type never share alterations in the same
oncogenes and tumor suppressor genes completely. Al-
though clear from a conceptual point of view, the relevant
genetic alterations underlying comparable tumors, such as




Dividing normal cell populations maintain the balance
between cell proliferation and cell loss. This is important for
maintaining a constant number of cells in a tissue. If there
is increased proliferation, decreased apoptosis, or both, un-
controlled growth occurs, and this may result in tumor
formation.17
Cell Proliferation
To assess the amount and distribution of cell proliferation
in paraffin-embedded tissues, monoclonal antibodies have
been developed to detect cell cycle modulators. Several
studies have used a monoclonal Ki-67 (MIB-1) and prolifer-
ating cell nuclear antigen (PCNA) antibody to study the pro-
liferative properties in BE and adenocarcinomas. An increased
number of proliferating cells and an expansion of the prolifer-
ative compartment were shown in BE and adenocarcino-
ma.18–20 PCNA immunostaining was mainly seen in the basal
cells of the neck/foveolar epithelial compartment of the glands
in BE. However, in mucosa with high-grade dysplasia, the
proliferative compartment extended upward into the super-
ficial layers of the glands.21–23 The Ki-67 staining pattern
also correlated with the histologic findings in BE: the num-
ber and the localization of Ki-67-positive nuclei were sig-
nificantly different between nondysplastic and low-grade
and high-grade dysplastic BE and adenocarcinoma.21,24–27
Apoptosis
Apoptosis, or programmed cell death, is one of the mech-
anisms responsible for cell loss. Apoptosis also provides a
protective mechanism by removing senescent, DNA-dam-
aged, or diseased cells that could either interfere with nor-
mal function or lead to neoplastic proliferation. Apoptosis
itself can be detected by use of immunohistochemical de-
tection of DNA fragmentation as markers for apoptosis. An
increase has been found in the apoptotic rate with increasing
histologic severity in intestinal metaplasia/dysplasia and
carcinoma,18 whereas others found few apoptotic cells in
Barrett’s high-grade dysplasia and adenocarcinoma.28,29
The Fas/APO-1 (CD95) gene encodes a transmembrane
protein that is involved in apoptosis. Loss of its expression
during carcinogenesis can result in interruption of the apo-
ptotic pathway. Hughes et al30 found that expression of Fas
on the cell surface by esophageal adenocarcinomas was
reduced or absent, whereas high levels of Fas mRNA were
detected in these tumors. They also showed in an esopha-
geal adenocarcinoma cancer cell line that wild-type Fas
protein is retained in the cytoplasm. Apparently, retention of
wild-type Fas protein in the cytoplasm may represent the
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mechanism by which malignant cells evade Fas-mediated
apoptosis.
The bcl-2 protooncogene encodes a protein that blocks
apoptosis.31 Bcl-2 expression is increased in reflux esoph-
agitis, nondysplastic BE, and low-grade dysplastic BE (70–
100% of cases) but is low or virtually absent in high-grade
dysplasia (0–25% of cases) and carcinomas (0–40% of
cases).21,26,29,32 Apparently, inhibition of apoptosis by over-
expression of bcl-2 protein occurs early in the dysplasia-to-
carcinoma sequence of BE. The resulting prolongation of
cell survival may promote neoplastic progression. As ma-
lignancy appears, cells acquire other ways of avoiding
apoptosis.
We can conclude that gradually increased and spatially
distinguished cell proliferation is a well-established perma-
nent alteration, whereas the role of apoptosis and bcl-2
seems less certain. The assessment of the ratio of prolifer-
ation to apoptosis may be more important than the isolated
assessment of either, and this may be a useful and sensitive
marker of neoplastic change in BE.19
Telomerase
During normal somatic cell division, telomeres shorten.
In contrast, immortalized and carcinoma cells show no loss
of telomere length during cell division. Telomerase is a
ribonucleoprotein complex that synthesizes telomeric DNA
located at the chromosome ends, thereby maintaining telo-
mere length. The increase in telomerase activity that accom-
panies most neoplastic and many preneoplastic conditions
may permit the emergence of a population of immortalized
cells, thereby facilitating the subsequent accumulation of
genetic mutations.33 By using in situ hybridization, Morales
et al34 detected only weak levels of telomerase RNA in cells
of the basal layer of normal squamous esophageal epithe-
lium, representing the population of stem cells. In contrast,
moderate to strong telomerase RNA expression, similar to
the zone of proliferation, was seen in Barrett’s metaplasia
(70% of cases), in 90% of the low-grade dysplasias, and in
100% of the high-grade dysplasias and esophageal adeno-
carcinomas. Interestingly, cardiac and fundic-type Barrett’s
mucosa, which is not associated with an increased risk of
adenocarcinoma, showed no telomerase RNA.
DNA CONTENT AND CHROMOSOMAL
ABNORMALITIES
DNA Content/Aneuploidy
A normal cell has a chromosome number of 2N, for
which the term diploid is applied. Cells reproduce by du-
plicating their content (4N) and then dividing in two. This
mammalian cell division cycle is divided into several dis-
tinct phases (Fig. 1). A cell with numeric aberrations is
designated as aneuploid.
When a suspension of single cells or nuclei is stained
with quantitative fluorescent DNA dye, the amount of flu-
orescence is directly proportional to the amount of DNA in
each cell. By using this technique, known as flow cytom-
etry, it has been shown that the evolution from normal
esophagus to premalignant Barrett’s metaplasia is fre-
quently associated with abnormal DNA content (aneuploi-
dy) and an increased G2/M fraction of the metaplastic
cells.35–37 Moreover, abnormal DNA content shows a cor-
relation with the histologic diagnosis of dysplasia and car-
cinoma.38,39 Flow cytometry also detects a subset of pa-
tients whose biopsy samples are histologically indefinite or
negative for dysplasia and carcinoma but who have DNA
content abnormalities similar to those otherwise seen only
in dysplasia and carcinoma.37,40 Therefore, this technique
(in combination with histology) may be useful in screening
patients with BE for early signs of malignant change.41
Indeed, prospective studies have shown that both aneu-
ploidy and dysplasia may be prognostic factors for malig-
nant transformation in BE36,41,42: 70% of the patients with
aneuploidy or increased G2/tetraploid fractions in biopsy
specimens obtained during initial endoscopic evaluation
developed high-grade dysplasia or cancer, whereas none of
the patients without flow cytometric abnormalities on initial
evaluation showed progression to invasive carcinoma or
high-grade dysplasia.36 Others have reported that histologic
dysplasia and aneuploidy are often discordant.43 Most dis-
cordance between several studies can be explained by meth-
odologic differences.
Several studies have reported that Barrett’s adenocarci-
nomas with abnormal nuclear DNA content are associated
with increased lymph node metastases, advanced disease,
and poorer survival.44–47 Others found no relationship be-
tween ploidy status and clinicopathologic parameters.48,49
It has been suggested that chromosome instability, tet-
raploidization, and asymmetric chromosome segregation
Figure 1. The cell cycle. Mitosis (M phase) is the process of nuclear
division. Replication of DNA occurs in the S (synthesis) phase. The
interval between M phase and S phase is called the G1 (gap) phase, and
the interval between the end of the S phase and the beginning of the M
phase is the G2 phase. Cells can exit the cell cycle and enter the G0
phase, which is the quiescent state.
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during cell division leading to aneuploidy are the result of
deregulated cell cycle genes with multiple functions that
normally exert active checks on the cell cycle processes,
including apoptosis and chromosome stability (e.g., p53 and
k-ras genes).50 This is supported by the finding that patients
with BE who show allelic loss of 17p (p53 gene locus) and
p53 mutations in diploid cells develop increased 4N (G2/
tetraploid) fractions and subsequently aneuploidy.51,52 As
discussed above, chromosomal instability is associated with
defects in mitotic checkpoint genes.16
Chromosomal Abnormalities
In BE and Barrett’s cancer, chromosomal alterations have
also been described based on karyotyping and in situ hy-
bridization studies. The most consistent numeric chromo-
somal abnormalities found in cytogenetic studies of dys-
plastic BE and adenocarcinoma is loss of the Y
chromosome.53–55 In esophageal adenocarcinoma, Y chro-
mosome loss is found in 31% to 93% of the tumors. In one
study, the frequency of Y chromosome loss in BE increased
along with the grade of dysplasia.27 Although BE and
Barrett’s adenocarcinoma occur more commonly in men, no
specific onco- or tumor suppressor genes have been as-
signed to the Y chromosome. Perhaps, as genetic instability
increases during malignant transformation of BE, Y chro-
mosome loss randomly occurs. Karyotyping revealed fre-
quent structural rearrangements in esophageal adenocarci-
nomas in the 1p, 3q, 11p-13, and 22p regions.53,56 Further,
trisomies for chromosomes 5 and 7 and translocations in-
volving chromosome 3 and 6 in BE have been described.55
Other frequent numeric aberrations in esophageal adenocar-
cinomas are overrepresentation of chromosomes 6, 7, 8, 11,
12, 14, and 20 and loss of chromosomes 4, 17, 18, and
21.53,54,56–58 In a subset of patients in whom premalignant
lesions were examined, aneusomy of chromosomes 6, 7, 11,
and 12 was found to be an early change, frequently present
in both BE and dysplastic regions. It remains to be deter-
mined whether any of these abnormalities are predictive
markers of progression to malignancy.
Microsatellite Instability
A form of genetic instability that has recently been iden-
tified is MSI. Microsatellites are mostly highly polymorph
short, tandem repeat DNA sequences. They are abundantly
and evenly distributed throughout the genome. MSI is
caused by a failure of the DNA mismatch repair system to
repair errors that occur during the replication of DNA and is
characterized by the accumulation of single nucleotide mu-
tations and alterations in length of the microsatellites. This
widespread MSI is a characteristic feature of tumors from
hereditary nonpolyposis coli cancer kindreds.59
Meltzer et al60 reported MSI at one or more chromosomal
loci of the five dinucleotide microsatellite repeats tested in
2 of 28 (7%) patients with Barrett’s metaplasia and 8 of 36
(22%) esophageal adenocarcinomas. Among 25 flow cy-
tometry-sorted adenocarcinomas, MSI occurred in 8 (32%).
In four of these eight, the diploid component of the tumor
showed MSI, suggesting that the MSI may develop as an
early event in BE-associated neoplastic progression. How-
ever, confusion remains about how to define the MSI phe-
nomenon—specifically, how many markers should be used
and how many must display MSI before the tumor is defined
as having MSI. According to more stringent MSI definition,
Gleeson et al61,62 found that MSI is infrequent in Barrett’s
adenocarcinomas and adenocarcinomas of the gastric car-
dia. Several studies have confirmed the low prevalence of
MSI (5–10%) in esophageal adenocarcinomas.63–67 Inter-
estingly, Wu et al67 found a trend toward improved survival
for patients with esophageal adenocarcinomas with MSI. It
is not known which mismatch repair genes are responsible
for the MSI observed in Barrett’s adenocarcinoma.
TUMOR SUPPRESSOR GENES
Microsatellite allelotyping or loss of heterozygosity anal-
ysis is a useful technique to define chromosomal regions of
deletion in carcinomas. The loss of heterozygosity analysis
uses the polymorphic microsatellite repeats, as mentioned
above. These microsatellites are present on all chromo-
somes and differ in size in the population and usually
between the paternal and maternal chromosome of an indi-
vidual. Polymerase chain reaction amplification of the mi-
crosatellites, followed by size separation, can identify chro-
mosomal arms or regions that are lost in the tumor
compared with normal tissue from the same person. Fre-
quent loss of one allele involving a chromosomal arm or
locus suggests the presence, at or near that locus, of a tumor
suppressor gene. Several groups have evaluated chromo-
somal regions for loss of heterozygosity in BE-associated
neoplasia and adenocarcinomas of the gastroesophageal
junction (Table 1). We will discuss the most common areas
of chromosomal loss with their target genes.
Chromosome 3p
Fragile sites are genomic regions that predispose to struc-
tural chromosome aberrations such as translocations or de-
letions. It is hypothesized that genes at fragile sites are
altered by chromosome rearrangements and thus contribute
to neoplastic growth.68 Chromosome band 3p14.3, encom-
passing the most inducible common fragile region, has been
cloned and the fragile histidine triad (FHIT) gene charac-
terized. In BE and associated adenocarcinomas, alterations
of the FHIT transcripts (FHIT mRNA lacking one or more
exons or homo- or hemizygous deletions of the gene) were
observed in 86% and 93%, respectively.69 Another study
found low rates of alterations in the FHIT open reading
frame in primary esophageal cancers, although lack of ex-
pression of FHIT transcripts was common in esophageal
cancer cell lines.70 However, aberrant FHIT transcripts have
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also been detected in normal, noncancerous tissues of the
gastrointestinal tract, bringing into doubt the role of FHIT as
a tumor suppressor.71 Its apparent involvement might sim-
ply reflect its location in an unstable region of the genome,
and FHIT might not be causally related to the tumorigenesis
of the esophagus.
Other candidate tumor suppressor genes on 3p are the von
Hippel Lindau (VHL) gene and the gene encoding the
peroxidase proliferator activated receptor-gamma (PPARg).
The genes are mutated in VHL disease and colon carcino-
mas, respectively.72,73 We screened adenocarcinomas of the
esophagus and gastroesophageal junction for genetic alter-
ations in the VHL and PPARg gene but could not detect
mutations in these genes. Because we and others detected a
high percentage of loss of heterozygosity at the VHL locus,66
other putative tumor suppressor genes at 3p could be involved
in the carcinogenesis of esophageal adenocarcinomas.
Chromosome 5q
Loss of heterozygosity at the mutated in colorectal cancer
(MCC) locus occurred in 63% of the patients with esopha-
geal carcinoma.74 So far, no reports have been published on
MCC mutation analysis in esophageal adenocarcinomas.
Observations from colorectal and gastric cancers suggest
that despite the high frequency of loss of heterozygosity of
the MCC gene, mutation of the retained MCC allele is
uncommon.75,76 This suggests that MCC does not function
as a tumor suppressor gene in gastrointestinal malignancies.










3p 14/22 (64) 3p24–26 VHL, PPARg 66
3q 11/17 (65) 3qter Unknown 178, 179
4q 57/81 (70) 4q21.1–22 Unknown 178, 180, 181
4q32–33 0
4q35 0
5q 10/22 (45) 5q11.2–13.3 MSH3 66, 74, 155, 178, 182
99/138 (72) 5q21–22 APC
MCC
IRF-1
5pq 4/9 (44) 5p12 Unknown 183
2/4 (50) 5q31.1 0
6q 10/17 (56) 6qter Unknown 178
9p 81/131 (61) 9p21.1–22 p15 66, 77, 80, 82, 84, 178
p16
IFNA
9q 8/17 (47) 9qter Unknown 178




12p 8/17 (47) 12pter Unknown 178
12q 11/17 (76) 12qter Unknown 178
13q 62/133 (47) Rb 65, 66, 88, 89, 184, 185
16q 31/48 (65) 16q22 E-cadherin 166
17p 124/166 (75) 17p11.2–13.3 OVCA1/2, HIC1 65, 178, 181, 184–187
TP53
17q 81/131 (63) 17q11.2–12 NF1, CSF3,
erbB-2, ITB4,
BRCA1




18q 40/68 (59) 18q22.1 DCC, DPC4 65, 66, 181
Smad-2
IFNA, interferon-alfa gene; NF1, neurofibromatosis gene; CSF3, colony stimulating factor 3; erbB-2, member of epidermal growth factor receptor family; ITB4,
integrin-beta 4; MSH3, DNA mismatch repair gene; Rb, retinoblastoma; VHL, von Hippel Lindau gene; PPARg, peroxidase proliferator-activated receptor-g; MCC,
mutated in colorectal cancer; APC, adenomatous polyposis coli; IRF-1, interferon regulatory factor 1; TOC, tylosis esophageal cancer gene; DCC, deleted in colorectal
carcinoma; DPC4, deleted in pancreatic carcinoma, locus 4; TP53, p53 tumor suppressor gene; BRCA1, breast cancer gene; WT2, Wilms’ tumor suppressor gene; H19,
gene involved in genomic imprinting; p57KIP2, a cyclin-dependent kinase inhibitor; HIC1, hypermethylated in cancer; OVCA1/2, ovarian cancer tumor suppressor genes
1 and 2; GH, growth hormone gene; Smad-2, signal transduction molecule involved in TGF-b signaling pathway.
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The adenomatous polyposis coli (APC) gene is also a
target of loss of heterozygosity on chromosome 5q21 to 22.
Loss of heterozygosity of the APC locus on 5q has been
found in esophageal adenocarcinomas and in the surround-
ing high-grade dysplastic BE. Further, the patterns of allelic
loss of the APC gene were identical in all stages of neo-
plastic progression, suggesting the emergence of a clonal
population of cells.74 However, loss of heterozygosity has
not been found in Barrett’s metaplasia or low-grade Bar-
rett’s dysplasia.77 Although APC mutations were found
frequently in colorectal cancers, a low rate of APC muta-
tions in esophageal cancers was detected,77–79 although in
most studies less than the entire coding sequence of the gene
was screened for mutations. This raised the possibility that
a gene distinct from APC may be the target of the frequent
loss of heterozygosity on 5q. Deletion of the APC locus may
simply be the result of large deletions on 5q and may not be
important in esophageal carcinogenesis.78 The interferon
regulatory factor 1 (IRF-1) gene or other genes on 5q31.1
may be the true target of frequent deletions on 5q that may
play an important role in the pathogenesis of most esopha-
geal carcinomas.78
Chromosome 9p
The p16 gene (MTS1, CDKN2A) encodes a 16-kD pro-
tein. It forms complexes with the cyclin-dependent kinases
CDK4 and CDK6, inhibiting their ability to phosphorylate
the retinoblastoma protein. Unphosphorylated retinoblas-
toma protein prevents the cell from entering the S phase of
the cell cycle. Thus, inactivation of this gene may lead to
uncontrolled cell growth. The p16 gene is located on chro-
mosome 9p at 9p21, a locus at which frequent allelic loss
occurs in esophageal adenocarcinomas.77,80 Point mutations
in exons 1 and 2 of the p16 gene are rare (approximately
5%) in esophageal adenocarcinomas, whereas p16 muta-
tions were more frequent in squamous cell carcino-
mas.70,81–83 Barrett et al84 reported a higher prevalence
(23%) of p16 gene mutations in adenocarcinomas with loss
of heterozygosity of 9p21. However, in this study only
aneuploid cell populations were investigated, which is not
representative for esophageal carcinomas in general; this
might explain the higher prevalence of p16 gene mutations.
It is possible that p16 is inactivated by different mecha-
nisms. Gonzalez et al77 reported homozygous deletions of
the p16 gene in 3 of 12 (25%) esophageal adenocarcinomas.
However, these genetic changes were not present in patients
with nondysplastic BE. Two studies showed that p16 pro-
moter methylation (with or without p16 loss of heterozy-
gosity) is a common mechanism of p16 inactivation during
neoplastic progression in BE and is already present in
nondysplastic premalignant BE.85,86 p16 inactivation may
indeed be a useful biomarker to stratify the risk of progres-
sion of Barrett’s metaplasia to esophageal cancer.87
Another tumor suppressor gene on 9p, p15 (MTS2/
CDKN2B), a close homolog of p16 and located 20 kb
centromeric, is rarely altered in various types of human
cancers, including esophageal adenocarcinomas.81,84
Chromosome 13q
The protein coded for by the normal retinoblastoma gene
is a critical regulatory molecule in the G1 phase of the cell
cycle. Mutations in this gene result in uncontrollable cell
proliferation and predispose to numerous human tumors.
Loss of heterozygosity of 13q has been shown in esophageal
adenocarcinomas88 and was associated with an unfavorable
survival rate.89 There are no reports on mutation analysis of
the retinoblastoma gene in esophageal adenocarcinomas,
but loss of normal retinoblastoma protein expression was
observed as the Barrett’s metaplasia progressed to dysplasia
and carcinoma, indicating accumulation of unstainable ab-
errant protein.18,90 Loss of heterozygosity of the retinoblas-
toma gene and retinoblastoma protein expression, as de-
tected by immunohistochemistry, however, were not
significantly correlated.
Chromosome 17p
Mutations and deletions of the p53 gene are the most
common genetic lesions in human cancers. The p53 protein
functions in a homotetrameric complex as a transcription
factor that induces expression of genes that facilitate cell
cycle arrest, DNA repair, and apoptosis (Fig. 2). One mutant
p53 protein in the tetrameric p53 complex abolishes the
function of the entire complex. Further, most mutant pro-
teins have a much longer half-life than the wild-type pro-
tein. This implies that when a cell harbors one inactivating
p53 mutation, the concentration of this protein will increase
relative to the product of the wild-type allele, and the
activity of the wild-type protein will be inhibited by com-
plexing with the mutant protein (dominant-negative). The
prolonged half-life of the mutant p53 protein and the con-
comitant increased cellular p53 concentration make visual-
ization by immunohistochemistry possible. Studies on BE
report a low percentage of metaplasia cases with p53 protein
accumulation.24,91–96 p53 accumulation increases in low-
grade dysplasia to high-grade dysplasia from less than 10%
to more than 70%.93,94,96–98 From the results of numerous
immunohistochemical studies, it is clear that in more than
50% of esophageal adenocarcinomas, pronounced p53 over-
expression is present.92,94–96,98–101 With molecular tech-
niques to detect p53 gene alterations such as single-strand
conformation polymorphism analysis, sequencing, and loss
of heterozygosity analysis, occasional cases of metaplasia
and low-grade dysplasia with p53 mutations have been
found.67,102,103 In high-grade dysplastic BE and invasive
adenocarcinoma, the prevalence of p53 mutations exceeds
40%, and p53 locus loss of heterozygosity in these conditions
is generally found at even higher rates.51,67,87,99,100,102–104 In
high-grade dysplasia and in esophageal adenocarcinoma, p53
mutations have been found even in diploid cell subpopulations
Vol. 233 c No. 3 Wijnhoven and Others 327
from aneuploid tumors.87,100 Further, allelic loss of chromo-
some 17p often occurs before the loss of 5q during neoplastic
progression.96,105 These findings suggest that p53 mutation is
an early event in esophageal adenocarcinogenesis.
In summary, there is overwhelming evidence that p53
gene alterations are early and frequent events in esophageal
adenocarcinomas and that this gene is associated with ma-
lignant transformation of BE. Although the prognostic sig-
nificance of p53 alterations has been suggested, p53 abnor-
mality alone is not sufficient to predict progression to cancer
or disease outcome.106–108
Chromosome 18q
Allelotype analysis has shown that allelic loss of 18q is
common in esophageal adenocarcinomas. However, muta-
tional analysis of the deleted in pancreatic cancer gene
(DPC4) revealed no mutations.109 Therefore, DPC4 is un-
likely to be the target gene on 18q21, and other candidates
such as the deleted in colorectal cancer gene or as yet
unidentified target genes may be involved.
PROTOONCOGENES
The protooncogenes encode a group of proteins involved
in signal transduction (from the plasma membrane to the
nucleus) or the regulation of gene expression. Mutated
protooncogenes are called oncogenes because most muta-
tions activate the proteins, resulting in overstimulation of
growth (Fig. 3).
Growth Factors and Their Receptors
EGF, TGF-a, and EGFRAn important family of growth
factors includes the ones that bind to the epidermal growth
factor receptor (EGFR), including epidermal growth factor
(EGF) and transforming growth factor alpha (TGF-a). EGF
has a stimulatory effect on epithelial cell proliferation in the
gastrointestinal tract and has been shown to be overex-
pressed in esophageal carcinomas. Although EGF is also
expressed in BE, the expression of EGF does not discrim-
inate between dysplastic and neoplastic epithelium.110
Overexpression of EGFR in the esophagus correlated with
the degree of mucosal dysplasia and the occurrence of
adenocarcinoma, suggesting that high expression levels
may reflect increased malignant transformation potential in
BE.25,110–112 Al-Kasspooles et al113 found EGFR gene am-
plification in 30% of the esophageal adenocarcinomas and
also in Barrett’s metaplasia, but no correlation with the level
of EGFR expression by immunohistochemistry. TGF-a is
structurally and functionally related to EGF. TGF-a expres-
sion is increased in metaplastic, dysplastic, and neoplastic
tissue of the esophagus compared with normal mucosa.110
The degree of abnormal expression becomes more marked
as dysplasia increases and correlates with the proliferative
indices in BE.22,110,114 In summary, EGF/TGF-a and their
receptor EGFR are important in the progression of normal
esophageal squamous epithelium to metaplasia, dysplasia,
and finally carcinoma and may be associated with autocrine
growth regulation in normal gastrointestinal mucosa and
neoplasia.115
Figure 2. p53 and cell cycle regulation. With DNA damage there is
upregulation of wild-type p53 protein. This leads to increased transcrip-
tion of p53-regulated genes (e.g., p21, bax-1, bcl-2), which inhibit the
cell cycle. This facilitates DNA repair, or the cell enters the apoptotic
pathway. In this way p53 provides genomic stability. Mutations in the
p53 gene render the p53 protein inactive, and the damaged DNA is
transmitted.
Figure 3. Signal transduction from the cell membrane to the nucleus
and the proteins (only protooncogene products) involved. Activation
(e.g., mutations) of the genes encoding growth factors, their receptors,
or the signal transduction pathway genes (ras, src, myc, bcl-2) can lead
to constitutive activation of the cell cycle. EGF, epidermal growth factor;
TGF, transforming growth factor.
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c-erbB2
The c-erbB2 protooncogene (HER2/neu; chromosome
17q21) encodes a transmembrane glycoprotein with intrin-
sic tyrosine kinase activity that is homologous to but distinct
from EGFR. c-erbB2 protein overexpression or amplifica-
tion of the c-erbB2 receptor gene occurs in approximately
10% to 70% of esophageal adenocarcinomas.44,110,116–120
Overexpression of c-erbB2 was not demonstrated in dys-
plastic BE, suggesting it is a late event in the dysplasia-to-
carcinoma sequence.117 c-erbB2 overexpression in adeno-
carcinomas correlated significantly with tumor invasion,
lymph node involvement, distant metastasis, and status of
residual tumor after resection.44,120
FGF
The fibroblast growth factors (FGFs) are potent mitogens
that possess angiogenic properties and the ability to regulate
growth and differentiation of various cell types. The expres-
sion of acidic and basic FGF (aFGF, bFGF) has also been
studied in esophageal adenocarcinoma and Barrett’s meta-
plasia. FGF is generally sequentially accumulated in the
progression from metaplasia to neoplasia. Esophageal
adenocarcinomas and high-grade dysplastic BE showed
enhanced expression of aFGF mRNA and protein (immu-
nohistochemistry) but not of bFGF when compared with
low-grade dysplasia and normal control epithelium.121,122
TGF-b
In contrast to TGF-a, TGF-b is a potent inhibitor of cell
proliferation, an inducer of differentiation in epithelial cells
of the intestine in vitro, and a suppressor of genomic insta-
bility.123 There is evidence that the TGF-b signaling path-
way is involved in the initiation and progression of esophageal
adenocarcinomas. First, TGF-b is expressed in nondysplastic
BE as well as esophageal adenocarcinomas.124,125 Second,
inactivating mutations occur in MADR2, an important com-
ponent of the signaling pathway for TGF-b, in colon can-
cers.126 The chromosomal localization of the MADR2 gene is
18q21, which frequently shows loss of heterozygosity in
esophageal adenocarcinomas. Finally, loss of expression of the
functional receptor for TGF-b (TGF-b receptor type II) ap-
pears to be associated with BE and esophageal adenocarcino-
mas.125,127,128 The exact role of TGF-b and its receptor in
Barrett’s adenocarcinomas needs to be clarified.
ras Family
The ras families of protooncogenes (H, K, and N) encode
specific proteins that appear to be essential components in
normal cell division and differentiation. ras proteins act as
signal-transducing molecules in the cytoplasm. ras has not
been shown to be mutated in most studies on BE and
esophageal adenocarcinomas.129–131 However, increased H-
ras expression in Barrett’s carcinoma and amplification of
the K-ras gene in esophageal adenocarcinomas have been
reported.132–134 Two studies reported, for the first time,
point mutations in K-ras in BE and in esophageal adeno-
carcinomas, but these were rare.135,136 Activation of the ras
protooncogenes seems to be of little importance in Barrett’s
adenocarcinomas, contrary to what has been observed in
other carcinomas of the gastrointestinal tract.
c-myc
The c-myc gene is located on chromosome 8q24 and
encodes a nuclear protein thought to regulate the transcrip-
tion of other genes important for cell growth.137 Activation
of the c-myc gene may contribute to tumor progression by
preventing cells from entering the G0 resting phase. Studies
suggest that c-myc is the target gene of the chromosome 8q
high-level amplifications found in esophageal adenocarci-
nomas.58,138–140 Using in situ hybridization, Abdelatif et
al134 found enhanced c-myc expression in dysplastic BE and
adenocarcinomas but not in nondysplastic Barrett’s mucosa.
In contrast, c-myc could not be detected immunohisto-
chemically in esophageal adenocarcinomas or BE.132 It is
unclear whether amplification or mutation of c-myc plays a
significant role in the malignant progression of BE, but it
appears to have limited prognostic value in human esopha-
geal carcinomas.141
src
The cellular oncogene c-src and its viral homolog v-src
encode 60-kD, cytoplasmic, membrane-associated, protein-
tyrosine kinases. A close correlation exists between ele-
vated specific kinase activity and cell transformation. src
may deregulate cell adhesion by anchorage-dependent
growth control, thereby maintaining cells in the prolifera-
tive state.142 src activity was found to be three to fourfold
greater in BE and sixfold greater in esophageal adenocar-
cinomas than in control tissues.143 Moreover, Jankowski et
al132 found that 20% of the cases of esophageal adenocar-
cinomas and BE expressed src. These data suggest a role for
src in the malignant transformation of BE and warrant
further investigation.
Prostaglandins
Cyclooxygenase (COX) catalyzes the rate-limiting step in
prostaglandin synthesis. There are two different isoforms of
COX: COX-1 and COX-2. COX-1 is constitutively ex-
pressed and is involved, for example, in cytoprotection of
the gastric mucosa. In contrast, COX-2 is normally absent in
most tissues but can be induced by proinflammatory or
mitogenic stimuli. COX-2 is involved in many processes
fundamental for tumor development: apoptosis, cell adhe-
sion, invasion and metastasis, and angiogenesis.144 Chronic
esophagitis is associated with the excessive mucosal pro-
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duction of prostaglandin E2, and bile acids stimulate
COX-2 expression in esophageal cells in vitro.145,146 Fur-
ther, COX-2 is expressed (determined by immunohisto-
chemistry or polymerase chain reaction or Western blotting)
in 70% to 80% of esophageal adenocarcinomas and also
incorresponding Barrett’s metaplasia.147,148 Inhibition of
COX-2 in esophageal cancer cell lines induced apoptotic
cell death and reduced the proliferative activity and synthe-
sis of prostaglandin E2.147,148 Among regular aspirin users,
a 40% to 50% or even greater reduction in esophageal
cancer risk was found.149,150 These data indicate that the
chemopreventive potential of nonsteroidal antiinflammato-
ries in esophageal adenocarcinomas, by repressing the in-
duction of COX-2 enzymes in esophagitis and Barrett’s
metaplasia, deserves further attention.
GENES INVOLVED IN CONTROLLING
THE CELL CYCLE
The progression of cells through the cell cycle is gov-
erned by genes encoding proteins transmitting positive (e.g.,
activated cyclins and cyclin-dependent kinases [CDKs]) and
negative (e.g., inhibitors of CDK) signals (Fig. 4). Cyclins
form a family of proteins that complex with CDKs. Phos-
phorylation of the retinoblastoma protein by cyclin D1-
CDK4/6 is correlated with the transition across the G1
checkpoint. Cyclin D1-CDK4/6 activity is regulated by
phosphorylation events and by CDK inhibitors, which bind
to the cyclin–CDK complex and inhibit its activity. This
cyclin–CDK inhibition impairs retinoblastoma protein
phosphorylation and thereby prevents the cell from entering
the cell cycle (S phase). The CDK inhibitors p15 and p16
have been already discussed. Another group of CDK inhib-
itors is the Cip/Kip family and includes p21, p27, and p57.
Cyclin D1
Cyclin D1 abnormalities, either gene amplification or
overexpression, lead to constitutive activation of the cyclin
D1-CDK4/6 pathway. Increased nuclear expression of cy-
clin D1 is observed in 22% to 64% of esophageal adeno-
carcinomas and is already present in Barrett’s metapla-
sia.89,151–153 The increased expression of cyclin D1 is
especially common in intestinal-type lesions and in tumors
with early T stage.151,154 Amplification of cyclin D1 gene
was observed in 16% to 26% of esophageal adenocarcino-
mas.154,155 However, cyclin D1 immunoreactivity was not
always associated with gene amplification.89,156 Therefore,
an additional regulatory mechanism of protein expression
probably exists.
p27Kip-1
The p27Kip1 (p27) gene is located on chromosome 12p13.
Overexpression of p27 induces a block during G1 in the cell
cycle. Singh et al157 found p27 protein expression and p27
mRNA to be increased in intensity and distributed through-
out the glands of high-grade dysplastic BE, indicating tran-
scriptional upregulation of p27. In contrast, low p27 protein
expression but elevated levels of p27 mRNA were found in
83% of esophageal adenocarcinomas, possibly because of
posttranscriptional regulation of the gene. In addition to
nuclear staining, cytoplasmic staining of p27 was noted in
48% and 26% of cases of dysplasia and carcinoma, respec-
tively.157 Loss of nuclear or cytoplasmic staining for p27
correlated with higher histologic grade, depth of invasion,
presence of lymph node metastasis, and shorter survival.157
These findings suggest that the cell cycle inhibitor p27 may
be overexpressed to counteract proliferative stimuli in BE-
associated dysplasia. Loss of p27 or altered subcellular
localization as the process becomes invasive suggests an
important role for this CDK inhibitor in preventing the
progression of BE to adenocarcinoma.124
p21WAF1/CIP1
The G1-S phase of the cell cycle can also be downregu-
lated by inhibition of CDKs by p21WAF1/CIP1 (p21). Nuclear
expression of p21 is upregulated by the wild-type p53 tumor
suppressor but not mutated p53.158 p21 expression was
elevated in Barrett’s tissue classified as indefinite for dys-
plasia, low-grade dysplasia, high-grade dysplasia, and Bar-
rett’s adenocarcinoma, but not in BE negative for dyspla-
sia.159 No relationship between p21 and p53 staining in
esophageal adenocarcinomas was found, indicating that
there are also p53-independent pathways for the upregula-
tion of p21.91,159 The elevated nuclear p21 expression in BE
Figure 4. Genes involved in cell cycle progression and inhibition. Cell
cycle progression from G1 into S phase requires activation of the cyclin-
dependent kinases (CDK4/6) in association with cyclin D1. This active
complex phosphorylates the retinoblastoma protein (Rb). Phosphory-
lated Rb releases Rb-bound transcription factors (E2F family). Free
E2Fs transactivate genes that are essential for entry into the S phase
and DNA replication. At the G1 checkpoint, there are also negative
regulatory signals controlling the cell cycle, namely inhibitors (p16, p21,
and p27) of activated cyclin–CDK complexes.
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and adenocarcinoma probably does not represent mutated
protein.160 p21 expression was significantly associated with
prognosis: patients with p21-positive tumors showed a bet-
ter prognosis than patients with p21-negative tumors.153
CELL–CELL ADHESION
It has long been known that cell–cell adhesion is gener-
ally reduced in human cancers. Reduced cell–cell adhesive-
ness removes contact inhibition of proliferation, thus allow-
ing escape from growth control signals. Moreover, invasion
and metastases, which are life-threatening properties of
malignant tumors, are considered to be later but critical
carcinogenic steps.
E-Cadherin-Catenin Complex
The E-cadherin-catenin complex is the prime mediator of
calcium-dependent cell–cell adhesion in normal epithelial
cells. In nonmalignant epithelia, E-cadherin and the catenins
show a membranous localization at intercellular borders. In
Barrett’s adenocarcinomas, reduced membranous expres-
sion of E-cadherin as well as the catenins is observed in
60% to 80% of tumors.161–164 Moreover, reduced expres-
sion of E-cadherin and a- and b-catenin correlated signifi-
cantly with unfavorable tumor stage, tumor grade, lymph
node metastases, and survival.164 Reduced expression has
also been shown to be associated with greater degrees of
dysplasia in BE.162,165 This suggests that the E-cadherin-
catenin complex may be useful as a marker for neoplastic
progression from Barrett’s metaplasia to adenocarcinoma
and metastases. No mutations could be detected in esopha-
geal adenocarcinomas, despite frequent loss of heterozygos-
ity of the E-cadherin locus at 16q22.166
Besides establishing cell–cell adhesion, b-catenin was
shown recently to function in cell signaling.167,168 Under
normal conditions, b-catenin is bound to the cytoplasmic
tail of E-cadherin. Free, unbound b-catenin in the cytoplasm
is kept low by rapid degradation of unbound b-catenin. To
be degraded, b-catenin is phosphorylated by a protein com-
plex, of which the APC protein is one of the members.
Inactivation of APC leads to an increase in cellular free
b-catenin that enters the nucleus of the cell, directly binds to
transcription factors, and activates gene expression. These
target genes are involved in promoting cellular proliferation
and migration, such as the c-myc oncogene and the cell
cycle regulator cyclin D1. Besides inactivation of APC,
mutations in phosphorylation sites of the b-catenin gene can
also lead to stabilization of the protein. In esophageal ade-
nocarcinomas, increased cytoplasmic and nuclear localiza-
tion of b-catenin has been observed,162 implying involve-
ment of APC inactivation or b-catenin mutations with
subsequent activation of the signal transduction pathway.
However, inactivation of APC is rare, and no mutations in
b-catenin could be detected in esophageal adenocarcino-
mas.79,169 This implies that other proteins that function in
this pathway should be involved.
Serine Protease System
The serine protease system has been shown to play an
important role in the invasive potential of a variety of
tumors by breaking down the extracellular matrix. Uroki-
nase plasminogen activator is a serine protease. High levels
of urokinase plasminogen activator were found in esopha-
geal adenocarcinomas170,171 and correlated with pTNM cat-
egory, tumor stage, lymphatic invasion, and survival.172
Therefore, urokinase plasminogen activator antigen content
could identify esophageal adenocarcinoma patients who
will develop early tumor recurrences, thus providing a more
accurate estimation of prognosis.
Figure 5. Genetic alterations in-
volved in the progression of Barrett’s
metaplasia toward Barrett’s adeno-
carcinoma. Alterations that occur in
the early stages are usually also
present in the advanced histologic
stages. In each histologic category,
the alterations are placed randomly;
there is no hierarchical order.
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CD44 Protein Family
CD44 is a family of glycoproteins involved in cell–cell
adhesion and cell–matrix interactions. As a result of alter-
native splicing of 10 exons (v1–10), more than 20 isoforms
have been described. CD44 standard (CD44s) and its ab-
normal transcripts (CD44v) have been detected in esopha-
geal adenocarcinoma.173–175 Increased CD44s expression
was seen in 50% to 66% of esophageal adenocarcinomas
(Dr. K.K. Krishnadath, personal communication, November
1997).173,175 In BE, CD44s but not CD44v6 expression
increases along with dysplasia and the proliferation rate, and
increased CD44v6 was seen in an early stage of malignant
transformation (Dr. K.K. Krishnadath, personal communica-
tion, November 1997).175 A significant correlation between
CD44s and v6 and v10 expression and clinicopathologic char-
acteristics has been reported (Dr. K.K. Krishnadath, personal
communication, November 1997),173,175 but further studies on
a larger patient cohort are required to validate the usefulness of
CD44s and isoforms in clinical decision making.
Cathepsin B
The cysteine protease cathepsin B (CTSB) gene, which
maps to 8p22, codes for a lysosomal enzyme that has been
shown to be overexpressed or to exhibit altered localization
in cancers.176 Overexpression or altered localization of
CTSB is thought to result in degradation of the basement
membrane, facilitating tumor invasion and metastasis.
Hughes et al177 found an amplicon at chromosome 8p22 to
23 resulting in CTSB gene amplification and overexpres-
sion. Moreover, abundant extracellular expression of CTSB
protein was found in 29 of 40 (73%) esophageal adenocar-
cinoma specimens.177 These data support an important role
for CTSB gene amplification and CTSB protein overexpres-
sion in esophageal adenocarcinomas.
SUMMARY AND CONCLUSIONS
There is a need for improved understanding of the mo-
lecular biology of BE and adenocarcinoma. Despite ongo-
ing efforts to characterize the molecular changes in BE, its
pathogenesis remains poorly understood. A wide variety of
genetic events and mechanisms appear to play a role in the
development and progression of BE-associated neoplastic
lesions (Fig. 5), but there is still no uniform molecular
pathway of progression. In fact, a surprising degree of
clonal heterogeneity in premalignant BE has been found,
consistent with a complex pattern of evolution of neoplastic
cell lineages rather than a simple linear pathway of
progression.
Meaningful clinical intervention in patients with BE is
still predicated on accurate histologic descriptions, but this
information can be supplemented by biomarkers of cell
proliferation and abnormalities in protooncogenes and tu-
mor suppressor genes. Many of these markers do not have
this potential: dysfunction of ras families of protooncogenes
and cell cycle genes such as c-myc and cyclin D1 are not
predictive of malignant transformation of BE. However,
development of Barrett’s adenocarcinoma is associated with
losses on chromosomes; for example, losses of 4q, 5q, 16q,
and 18q are frequently observed. Results of these studies are
promising but need further attention. The same can be said
about cell–cell adhesion molecules and growth factors and
their receptors (e.g., EGFR, c-erbB2, src, and the prosta-
glandins). Abnormalities involving the p16 and p53 tumor
suppressor genes and aneuploidy or increased 4N popula-
tions are among the most common somatic genetic lesions
in the progression from BE to esophageal adenocarcinoma.
These biomarkers are potential candidates for objective
molecular markers that can be used in combination with
histologic staging to stratify a patient’s risk of progressing
to esophageal adenocarcinoma.
In the next several years, the subsequent genetic events
critical for the initiation and progression of Barrett’s ade-
nocarcinoma will be characterized and may be clinically
useful as biomarkers for early cancer detection or prognos-
tication. With the disturbing increase in the incidence of
Barrett’s adenocarcinomas, further research into this area is
vital.
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